The healthcare group continues to do well…and the recent rally has taken one big cap name from this group up to a key technical juncture: Johnson & Johnson (JNJ). Back in the fall, JNJ was able to successfully test its 200 week moving average for the third time in less than two years. Its 17% rally off those autumn lows has taken the stock back up near its all-time highs of the $150. In other words, it’s testing its “double-top” highs from 2018…which is also the top line of an ascending triangle pattern. (As you can see from the chart attached below, the bottom line of that pattern is its 200 week MA.) Therefore, if JNJ can break above the $150 level in a meaningful way, it’s going to be very, very bullish for the stock.

We do need to point out, however, that JNJ become quite overbought on both a short-term and intermediate-term basis. Of course, the same thing can be said about a lot of stocks. In fact, this could have been said about a lot of stocks over the past several weeks…and yet many of these stocks have kept on climbing. Therefore, JNJ just might be able to break-out immediately…even though it is quite overbought.

So what’s our take on the stock right now??? Well, we think the stock will probably pull-back a little bit over the near-term to work-off his overbought condition (or at least take a “breather” with a sideways move) before it breaks above the important $150 level in powerful way. However, if/when JNJ does break above that key resistance level of $150 in a meaningful way (whether now or after a breather), it’s going to be very bullish for the stock.

To see comments like these on a daily basis (and my ...

• New uncertainties have developed in the market place.
• However, the last round of “uncertainty” didn’t cause any problems, so complacency is high.
• This rally is liquidity fueled, not fundamentally fueled (just ask Drunkenmiller & Tepper).
• The Fed knows they’re creating ...

In our "Morning Comment" on Friday morning, we highlighted WFC...and turned bearish on the stock. Since then it has fallen over 8%.

That's a very big move over just three trading days, so any short-term traders who might ...

Every weekend, we write a piece we call "The Weekly Top 10". However, this is NOT a regurgitation of Barron's or the weekend edition of the WSJ. Instead, we try to cover the issues most people are not focusing ...

Back in late October, we turned much more bullish on the biotech sector when the IBB biotech ETF broke back above its summer highs. The IBB rallied 16% over the next two months…outperforming the S&P 500 (which has rallied 7 ...

We have stated several times in recent days that the broad stock market is overbought. However, we have not shown WHY we believe this to be true. Our apologies. Here is a chart that supports our case:

The S&P 500 ...

• Yesterday’s bounce was quite understandable, but a lot of upside follow-through near-term is doubtful.
• The situation with Iran has been pushed to the sidelines…which is obviously positive, but it’s far from over.
• Besides, the stock market is overbought…and earning season ...

• No casualties means President Trump will not escalate the situation in Iraq/Iran further at this time.
• However, the bounce could/should be limited…because the decline was very muted.
• There are still a lot of unanswered questions…with earnings guidance & ...

In our full edition of the "Morning Comment," we touched on the following subjects:

• Most people liked yesterday’s midday bounce. We did not. It shows there’s too much complacency out there.
• The market is overbought after its big 2019 & ...

• Iran is one of the reasons the U.S. does not want North Korea to become a nuclear power.
• Since N. Korea is connected to the Iran issue, so is China.
• These new uncertainties should keep oil elevated for longer ...

Morning Comment: Update on the FAANG charts.

• Yesterday’s decline was meaningless. Today’s action should be equally meaningless.
• The FAANGs continued to be leaders early in 2019, but lost that status in the spring.
• However, those FAANG stocks have regained A ...

We’ve heard some very different predictions for the direction of interest rates over the past few days. Just yesterday, Citigroup said that they expect the yield on the 10yr note to decline down to the 1.25% level next year…while ...